Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

a milestone payment from Johnson &

Johnson Pharmaceutical Research and Development, LLC (J&JPRD) triggered

by J&JPRD's selection of a compound targeting the Cathepsin S enzyme as

a development candidate emerging from a collaboration with Sunesis.

-- Lesley A. Stolz, Ph.D., joined Sunesis in November 2007 as Vice

President, Corporate and Business Development.

Financial Highlights

-- Revenue totaled $2.0 million and $9.7 million, respectively, for the

three months and year ended December 31, 2007, compared to $2.0 million

and $13.7 million for the three months and year ended December 31,

2006. The decrease in revenue year-over-year was primarily due to

lower milestone payments from Merck & Co., Inc. in 2007 compared to

2006.

-- Research and development (R&D) expense was $8.3 million for the fourth

quarter of 2007, compared to $8.5 million for the same period in 2006.

R&D expense for the year ended December 31, 2007 totaled $36.1 million,

compared to $35.6 million in 2006. The year-over-year increase in R&D

expense was primarily due to increased clinical trial activity for SNS-

595 and preclinical program costs, partially offset by lower headcount

and lower R&D expense associated with SNS-032 and SNS-314 due to

reduced research activities in these programs.

-- General and administrative (G&A) expense for the fourth quarter of 2007

was $2.8 million, compared to $3.4 million for the fourth quarter of

2006. For the year ended December 31, 2007, G&A expense was $13.6

million, compared to $12.3 million in 2006. The quarter-over-quarter

decrease primarily resulted from lower professional services expense in

2007 compared to 2006. The year-over-year increase in G&A expense was

primarily due to increased non-cash stock-based compensation expense,
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Rockville, MD (PRWEB) July 29, 2014 ... (ITI), a vaccine pioneer in the biotechnology industry, ... firm Newport Coast Securities, Inc. to explore financing ... commercializing LAMP-vax technology, a breakthrough vaccine platform with ... immunotherapy market. The company exclusively licensed the well-established ...
(Date:7/29/2014)... VONORE, Tenn. (PRWEB) July 29, 2014 ... leader in biomass feedstock supply innovation and supply ... new proprietary feedstock management systems, Energy Grangeā„¢ and ... years of R&D and in-the-field testing aimed at ... and offering benefits to landowners, farmers and feedstock ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 DisasterTalk is a ... people where cell phone masts or other transmitters are down. ... 100 feet away without the need for any Wi-Fi, and ... ranges. , The new app has launched as a ... are at very high risk of being affected by natural ...
(Date:7/29/2014)... -- United Therapeutics Corporation (NASDAQ: UTHR ... the second quarter ended June 30, 2014. ... medicines are reaching increasing numbers of patients ... Martine Rothblatt, Ph.D., United Therapeutics, Chairman and ... quarter of our extended-release tablet called Orenitram ...
Breaking Biology Technology:Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3Genera Energy Introduces Proprietary Feedstock Management Systems 2Genera Energy Introduces Proprietary Feedstock Management Systems 3Genera Energy Introduces Proprietary Feedstock Management Systems 4DisasterTalk App Could Save Lives as Report Reveals 8% of US Homes at Very High Risk of Natural Disaster 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13
... Pharmaceutical and ... Biotech Industries, ... short-term and long-term biomaterials storage, sample,management and cold chain logistics, ... inaugural,Biorepositories 2008, the only U.S.-based event for the pharmaceutical and,biotech ...
... portfolio, CORAL GABLES, Fla., June 23 ... pharmaceutical company specializing in,dermatology, today announced it ... which Stiefel Laboratories will acquire Barrier Therapeutics,Inc. ... a two-step,transaction, a tender offer followed by ...
... JOLLA, Calif., June 23 TorreyPines Therapeutics,Inc. (Nasdaq: ... Kurtz, President and,Chief Executive Officer, will present data ... safety, tolerability and efficacy of three doses,of tezampanel ... the,50th Annual Scientific Meeting of the American Headache ...
Cached Biology Technology:BioStorage Technologies Announces Platinum Sponsorship of Biorepositories 2008 2Barrier Therapeutics to Merge Into Stiefel Laboratories 2Barrier Therapeutics to Merge Into Stiefel Laboratories 3Barrier Therapeutics to Merge Into Stiefel Laboratories 4Barrier Therapeutics to Merge Into Stiefel Laboratories 5TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society 2
(Date:7/29/2014)... you,ve ever ordered the wrong food at a restaurant, don,t ... have less to do with what you want and more ... analyzing 217 menus and the selections of over 300 diners, ... Journal of Hospitality Management showed that when it comes ... what you see on the menu and how you imagine ...
(Date:7/29/2014)... Research and Markets  has announced the ... Market 2014-2018" report to their offering. ... term BI refers to applications and technologies that are ... about a company,s operations. BI help organizations to acquire ... example, metrics on sales, production, and internal operations. ...
(Date:7/29/2014)... Swimming microorganisms, such as bacteria and spermatozoa, are subjected ... forces exerted by the surrounding fluid. Such low-level ... found that the direction of propulsion made possible by ... viscoelastic fluid. These findings have been published in ... Energies and Atomic Energy Commission (CEA), in Le Barp, ...
Breaking Biology News(10 mins):Menu secrets that can make you slim by design 2Global SaaS-based Business Intelligence (BI) Market 2014-2018 2Optimum inertial self-propulsion design for snowman-like nanorobot 2
... to interact with the genes her unborn child inherits and ... research funded by the Wellcome Trust and the British Heart ... Molecular Genetics , suggests that mothers who eat a high ... the health of their offspring at risk. Congenital heart ...
... a new means of determining the sex of skeletal human ... the wake of disasters, the studying of ancient remains and ... able to determine the sex of skeletal remains by visually ... coxa. "This technique is accurate, but is not without its ...
... Ga. - Robots that revolutionized gynecologic and urologic surgery in ... least a portion of their diseased thyroid gland without the ... just under the Adam,s apple and controls the body,s metabolic ... cancerous disease can more than double its size. Dr. David ...
Cached Biology News:Maternal diet and genes interact to affect heart development 2Maternal diet and genes interact to affect heart development 3Hips don't lie: Researchers find more accurate technique to determine sex of skeletal remains 2Robots preclude neck incision for thyroid surgery 2
EPH electrode, anode, 1. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
GENOMIPHI HY KIT 1000 RXN, 1 EA. Category: Genomics DNA Amplification....
... Kit is an aqueous-based mounting reagent that ... This formulation of antifade minimizes the initial ... fluorophores that is often seen with the ... with the blue-fluorescent nucleic acid counterstain ...
SlowFade Antifade Kit with DAPI...
Biology Products: